|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Ablation of SRC-3 or PFKFB4 suppresses breast tumour growth in mice and prevents metastasis to the lung from an orthotopic setting, as does Ser857Ala-mutant SRC-3.
|
29615789 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although total SRC3 is selectively found at enhancer regions, SRC3-pS543 is recruited to promoters of ERα responsive genes, both in the MCF7 cell line and primary breast tumor specimens.
|
26369632 |
2016 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Beyond furnishing critical mechanistic insights into SRC-3's involvement in mammary tumor progression, these findings provide opportunities to develop new approaches for breast cancer diagnosis and intervention.
|
21047941 |
2011 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Elevated expression of steroid receptor coactivator-3 (SRC-3), a member of the p160 family of nuclear receptor coactivators, has been implicated in tamoxifen resistance of breast tumors while the involvement of the two other members of this family, SRC-1 and SRC-2, is less well characterized.
|
21059860 |
2011 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
NCOA3 is a known low to moderate-risk breast cancer susceptibility gene, amplified in 5-10% and over expressed in about 60% of breast tumours.
|
21601620 |
2011 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
|
20332317 |
2010 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data link the SMRT corepressor directly with SRC family coactivators in positive regulation of ERalpha-dependent gene expression and, taken with the positive correlation found for SMRT and SRC-3 in human breast tumors, suggest that SMRT can promote ERalpha- and SRC-3-dependent gene expression in breast cancer.
|
20392877 |
2010 |
|
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Phosphorylated Y1357 is increased in HER2/neu (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2) mammary tumor epithelia and is required to modulate AIB1/SRC-3 coactivation of estrogen receptor alpha (ERalpha), progesterone receptor B, NF-kappaB, and AP-1-dependent promoters. c-Abl (v-Abl Abelson murine leukemia viral oncogene homolog 1) tyrosine kinase directly phosphorylates AIB1/SRC-3 at Y1357 and modulates the association of AIB1 with c-Abl, ERalpha, the transcriptional cofactor p300, and the methyltransferase coactivator-associated arginine methyltransferase 1, CARM1.
|
18765637 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
|
17636398 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
|
18827493 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
In 560 human breast tumors, AIB1 expression was found to be positively associated with PEA3, MMP2, and MMP9.
|
18644862 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines.
|
16670003 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA.
|
16940181 |
2006 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
SRC-3 was localised within epithelial cells of breast tumour tissue and was co-localised with ER-alpha and ER-beta, (n=112).
|
17158759 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
E6AP mediates regulated proteasomal degradation of the nuclear receptor coactivator amplified in breast cancer 1 in immortalized cells.
|
16951183 |
2006 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice.
|
15550471 |
2005 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NCOA3 is overexpressed in approximately 60% of primary human breast tumors, and high levels of NCOA3 expression are associated with tamoxifen resistance and worse survival rate.
|
15788663 |
2005 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
NCOA3 is overexpressed in approximately 60% of primary human breast tumors, and high levels of NCOA3 expression are associated with tamoxifen resistance and worse survival rate.
|
15788663 |
2005 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance.
|
15169882 |
2004 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells.
|
15548698 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
TOP1, TFAP2C, and (particularly) NCOA3 may be prognostic indicators for patients with breast tumors.
|
12833450 |
2003 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Poly Q encoding sequences of AIB1 from 107 DNA samples, including breast cancer cell lines, sporadic primary breast tumours, and blood samples from BRCA1/BRCA2 mutation carriers and the general population, were resolved by PCR/cloning followed by sequencing of each individual clone.
|
14684685 |
2003 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Clinical significance of AIB1 expression in human breast cancer.
|
14503806 |
2003 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
TOP1, TFAP2C, and (particularly) NCOA3 may be prognostic indicators for patients with breast tumors.
|
12833450 |
2003 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Overexpression of AIB1-Delta3 may thus play an important role in sensitizing breast tumor cells to hormone or growth factor stimulation.
|
11502741 |
2001 |